About us
The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients.
Projects
Participation
Events
Press
Contact
Breadcrumbs
The ethical dimensions of studies with allowed treatment switching
Professor Dr Daniel Strech, Hanover Medical School (MHH)
Criteria for treatment switching in oncological studies
Professor Dr Bernhard Wörmann, German Society of Haematology and Oncology (DGHO)
The role of the Federal Institute for Drugs and Medical Devices (BfArM) in the planning, authorization and acceptance of clinical studies and their results in oncology
PD Dr Thomas Sudhop, BfArM
Evaluation of treatment switching in the Institute’s assessments
Dr Volker Vervölgyi, IQWiG
Methods to estimate survival time after treatment switching in oncology – overview and practical considerations
Dr Norbert Hollaender, Novartis
Adjustment of overall survival (OS) after crossover – aspects from the perspective of the benefit assessment
Professor Dr Ulrich Mansmann, Ludwig Maximilians University (LMU) Munich
Programme
Abstracts of the presentations
